It remains to be seen whether ribavirin will be part of ABT’s all-oral HCV combination, when all is said and done. The components will likely include ABT-450 (a PI), ABT-267 (an NS5A inhibitor), and one of the non-nukes (ABT-072 or ABT-333).
ABT-450 requires boosting with ritonavir, so there are at least four drugs in the cocktail (and possibly five) if you count ritonavir.
Market Data 
Markets 
AI
